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ARTICLE
JNK1/2 represses Lkb1-deﬁciency-induced lung
squamous cell carcinoma progression
Jian Liu 1, Tianyuan Wang 2,11, Chad J. Creighton 3,4,5,11, San-Pin Wu 1,11, Madhumita Ray 1,
Kyathanahalli S. Janardhan 6, Cynthia J. Willson 6, Sung-Nam Cho 7, Patricia D. Castro 8,
Michael M. Ittmann 8, Jian-Liang Li 2, Roger J. Davis 9,10 & Francesco J. DeMayo 1
Mechanisms of lung squamous cell carcinoma (LSCC) development are poorly understood.
Here, we report that JNK1/2 activities attenuate Lkb1-deﬁciency-driven LSCC initiation and
progression through repressing ΔNp63 signaling. In vivo Lkb1 ablation alone is sufﬁcient to
induce LSCC development by reducing MKK7 levels and JNK1/2 activities, independent of the
AMPKα and mTOR pathways. JNK1/2 activities is positively regulated by MKK7 during LSCC
development. Pharmaceutically elevated JNK1/2 activities abates Lkb1 dependent LSCC for-
mation while compound mutations of Jnk1/2 and Lkb1 further accelerate LSCC progression.
JNK1/2 is inactivated in a substantial proportion of human LSCC and JNK1/2 activities
positively correlates with survival rates of lung, cervical and head and neck squamous cell
carcinoma patients. These ﬁndings not only determine a suppressive role of the stress
response regulators JNK1/2 on LSCC development by acting downstream of the key LSCC
suppresser Lkb1, but also demonstrate activating JNK1/2 activities as a therapeutic approach
against LSCC.
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Precision medicine has been enjoying successes in recentyears, especially with the application of genomics-drivencancer therapy1. For example, the discovery of key drivers
(e.g. EGFR and ALK) of human lung adenocarcinoma using
genetic mouse models has led to the development of targeted
therapies2. Therefore, identifying cancer driver mutations in
human cancers is valuable for targeted therapy2,3.
Lung squamous cell carcinomas (LSCCs) comprise about
25–30% of all lung cancers, which is the leading cause of cancer-
related death in the United States and worldwide4. Human LSCC
develops from normal airway epithelium and progresses through
hyperplasia, squamous metaplasia, dysplasia, and carcinoma5.
SCC characteristics emerge at the squamous metaplasia stage in
the nests of neoplastic squamous cells with an increase in marker
expression (e.g. p63)6. Genomic analysis of human LSCC tumors
has provided a comprehensive landscape of the molecular
alterations, including frequently mutated genes (e.g., TP53, PTEN
and LKB1) and altered pathways (e.g., SOX2, PI(3)K/LKB1,
EGFR/FGFR/RAS) associated with this disease7,8. Several pre-
clinical models show that mice carrying compound mutations
develop LSCC, as evidenced by studies on KrasG12D/Lkb1loss,
Sox2OX/Lkb1loss, Ptenloss/Lkb1loss, and Cdkn2aloss/Ptenloss/
Sox2OX mice8–11. In contrast, mutations in one single gene lead to
lung adenocarcinomas (ADs), as shown by Trp53 deﬁciency, Pten
ablation, KrasG12D or EgfrL858R activation and Sox2 over-
expression (Sox2OX)10,12–14. To date, the question on whether
LSCC can be initiated by a single gene mutation remains out-
standing and the underlying mechanism of LSCC formation and
progression remains unclear4,15.
In addition to genetic causes, LSCC development is frequently
impacted by environmental stresses16, as documented in expo-
sures to smoking17, air pollution18 and radon19. Upon envir-
onmental challenges, stress signaling, such as the MKK7-JNK1/2
pathway, participates in induction of inﬂammation responses
and changes of expression of cancer-related genes20–22. The
JNK1/2 signaling has been linked to cancers in lung, breast and
colon and ovary, mainly related to adenocarcinoma cells23.
However, the JNK1/2 pathway could act as either a positive
or a negative regulator in tumorigenesis24–26. It is not clear
what is the role of JNK1/2 signaling in SCC development despite
that JNK1/2 is related to LSCC-associated environmental
challenges.
LKB1 (also called STK11, serine/threonine kinase 11) is a fre-
quently mutated gene in human LSCCs8,9. LKB1 has been shown
as an important suppressor of LSCC, supported by observations
that Lkb1 deﬁciency in mouse lungs drives LSCC development in
conjunction with additional mutations8–10. However, ablation of
Lkb1 alone in mouse lung using adenovirus-Cre (Ad-Cre) via
intranasal delivery does not cause pulmonary neoplasia8,9. This
may be due to the limitation on efﬁciency of intranasal delivery of
Cre into large airways where human LSCC is frequently
initiated5,27. Using a previously generated codon-optimized Cre
recombinase under the control of the Club Cell Secretory Protein
promoter (CCSPiCre) for all airway epithelial cells, including cells
of large airways, we found that Lkb1 deﬁciency by itself is sufﬁ-
cient to induce LSCC. In contrast, no LSCC was induced after
manipulation of other ﬁve candidate genes that have frequent
mutations in human LSCCs, including TP53, PTEN, ERRFI1,
SMAD4 and KRAS7. We further identiﬁed the stress response
pathway MKK7-JNK1/2 as downstream effectors of Lkb1 in
suppressing ΔNp63 signaling during LSCC development. The
observations that LSCC patients with higher JNK1/2 activities
have better survival rates and activating JNK1/2 activities
attenuate LSCC progression suggest targeting the JNK1/2-medi-
ated stress response pathway as a way to combat against LSCC.
Results
Lkb1 deﬁciency alone is sufﬁcient to induce LSCC. Ablation of
Lkb1 in mouse airway was achieved by crossing Lkb1 ﬂoxed mice
with CCSPiCre mice (Lkb1d/d: CCSPiCreLkb1f/f) (Supplementary
Fig. 1a–b). Strikingly, LSCCs were found in Lkb1d/d mice, as early
as, 11 months old in addition to AD (Fig. 1a and Supplementary
Fig. 2a–b; Table 1 and Supplementary Data 1−2). LSCC lesions in
Lkb1d/d mice displayed typical nests of neoplastic squamous cells,
some with keratinization and most with inﬁltrates of neutrophils
(Fig. 1a). Cells in the lesions exhibited positive staining of LSCC
clinical markers (p63, ΔNp63 and CK5) and lack of lung AD
marker TTF1 expression (Fig. 1b and Supplementary Fig. 1c–d)
28. Two subpopulations of SCC cells are observed at lesions sites
based on levels of LSCC markers p63 and ΔNp63. Cells in nests of
neoplastic squamous cells (Fig. 1b, region IV and Supplementary
Fig. 1c–d) exhibited higher levels of both p63 and ΔNp63. In
contrast, SCC cells adjacent to large airways (Fig. 1b, region III
and Supplementary Fig. 1c–d) have relatively lower expression of
p63 and ΔNp63, which could be cells at the early phase of LSCC.
Meanwhile, progressive lung SCC developmental stages (SCC-
DSs) were also observed after Lkb1 ablation (Supplementary
Data 1-2), including epithelial hyperplasia (5.4%) (Supplementary
Fig. 1e), squamous metaplasia (1.8%) (Supplementary Fig. 1e),
adenocarcinoma with squamous differentiation (10.7%) (Sup-
plementary Fig. 1f) and adenosquamous carcinoma (ASC) (5.4%)
(Supplementary Fig. 1g). These lung SCC-DSs showed the focal
or diffuse positive staining of p63 and CK5, respectively, as well as
the focal weak or negative staining of TTF1 (Supplementary
Fig. 1e–g). On the other hand, unlike Lkb1 ablation, no lung SCCs
and SCC-DSs were induced after individual manipulation of ﬁve
known SCC-associated genes Pten, p53, Errﬁ1 (Mig6), Kras and
Smad4 (Table 1 and Supplementary Data 1−2). Instead, lungs of
Pten deletion, P53 ablation, Errﬁ1 knockout or KrasG12D activa-
tion had AD tumors, adenomas and atypical adenomatous
hyperplasia that showed opposite proﬁles of marker expression
compared with lung SCCs in Lkb1d/d mice (Table 1 and Sup-
plementary Fig. 2b−f)8,29. Moreover, loss of Smad4 exhibited no
histomorphologic change in lungs (Supplementary Fig. 2g–h),
consistent with a previous report13. In summary, these ﬁndings
reveal a unique capacity of Lkb1 deﬁciency in the induction of
lung SCCs and SCC-DSs.
Transcriptome proﬁling demonstrates that the Lkb1-deﬁ-
cient mouse LSCC exhibited a high degree of positive
correlation with human LSCC, especially with LSCC Subtypes
2a and 2b, compared to other subtypes of human lung cancers
(Fig. 1c and Supplementary Fig. 3a)30. These ﬁndings support
that Lkb1d/d mouse LSCCs closely resemble human LSCCs
at the transcriptome level. Functionally, Lkb1 deﬁciency altered
expression of genes that are enriched in functions of cell
movement, morphology, death and survival (Supplementary
Table 1), reﬂecting the histological observations. Interestingly,
the known LKB1 downstream target AMPKα31 did not change
its phosphorylation levels in the absence of LKB1 at the SCC
stage (Fig. 1d). Another LKB1 target mTOR even showed
reduced levels of phosphorylation, in contrary to the
previously reported role of LKB1 in suppressing mTOR
activity (Fig. 1d)32. Like the observations in SCCs, no
signiﬁcant changes of AMPKα and mTOR phosphorylation
levels were found in 1- and 3-month old mouse lungs at the
pretumor stage in response to Lkb1 deﬁciency (Fig. 1e and
Supplementary Fig. 3b–c). These results suggest that LKB1
utilizes pathways other than those of known cancer-associated
ones for LSCC development. Close examination of genes
altered by Lkb1 deﬁciency via ingenuity pathway analysis (IPA)
revealed JNK1/2, P38, NFĸB and ERK1/2 as the common
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downstream pathways for candidate upstream regulators of
Lkb1 responsive genes (Table 2 and Supplementary Data 3).
Gene set enrichment analysis (GSEA) further showed that the
P-JNK1/2 induced pathway, as the top enriched pathway,
negatively correlated with the Lkb1 deﬁciency gene signature
(Fig. 1f and Supplementary Table 4). These observations
establish an association between Lkb1 deﬁciency and reduced
JNK1/2 activities in LSCC.
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Fig. 1 Lkb1 ablation alone induces LSCC development with negative JNK1/2 activities. a Upper panel: Gross appearance of lung tumors in 13-month-old
(13M) CCSPiCreLkb1f/f (Lkb1d/d) mice. SCC squamous cell carcinoma; SCC was labeled by a dash cycle and an arrow (upper panel). Scale bar: 0.5 cm. Lower
panel: Representative 13M Lkb1d/d mouse lung SCC (H&E). Inﬁltrates of neutrophils were commonly associated with SCC nests (black arrow, lower panel).
Keratinization was frequently present in SCCs (blue arrow, lower panel). Scale bar: 60 μm. b Representative immunohistochemistry (IHC) staining of 13M
Lkb1d/d mouse lung SCC. SCC markers: p63 and ΔNp63; AD marker: TTF1. “+” means the expression is mild or moderate, and “++” means the expression
is strong. Dashes outline: Regions of interest. Positive staining is indicated in some panels by green arrows. Scale bar: 10 μm. c Alignment of the gene
signature of 13-month-old Lkb1d/d mouse lung SCC tumors with Takeuchi human lung cancer database (GSE11969). A score greater than zero indicates
a positive correlation with the murine gene signature of 13-month-old Lkb1d/d mouse. AD adenocarcinoma, ASC adenosquamous carcinoma, LCC large-cell
carcinoma, LCNEC large-cell neuroendocrine carcinoma, SCC squamous cell carcinoma, SCLC small cell lung cancer. ANOVA (Tukey−Kramer Multiple
Comparisons (TKMC) Test) was performed and error bar is SEM; *P < 0.05; ***P < 0.001. d Western blot (WB) analysis (n= 5) of protein expression in
13-month-old (13M) mice. e WB analysis (n= 3) of protein expression in 3-month-old (3M) mice. f Gene set enrichment analysis (GSEA) of pre-ranked
genes detected in microarrays analysis of 13-month-old Lkb1d/d mouse lung SCCs. All detected genes (Supplementary Data 3) were ranked based on their
fold changes (Lkb1d/d SCC vs. WT) from high (the left terminal of X-axis) to low (the right terminal of X-axis)
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JNK1/2 is inactivated in Lkb1-null induced mouse LSCCs. To
further investigate the association between reduced JNK1/2
activities and LSCC development, we examined the phosphor-
ylation of JNK1/2, P38, NFĸB and ERK1/2. Indeed, JNK1/2
phosphorylation was almost abolished in Lkb1d/d mouse LSCCs
with the most robust change among all tested candidates (Fig. 2a).
Reduced JNK1/2 phosphorylation is also seen in LSCC compared
to normal upper airway tissues by immunohistochemistry (IHC)
assay (Fig. 2b), consistent with western blot results. Moreover,
JNK1/2 phosphorylation has an opposite expression pattern to
that of ΔNp63 and p63 (Fig. 1b), which further supports a
negative correlation between JNK1/2 activities and LSCC in situ.
Next, the timing of change of JNK1/2 activities in response
to Lkb1 deﬁciency was examined to determine the sequence of
events between JNK1/2 inactivation and LSCC development. We
took advantage of the CCSPiCreLkb1f/fPtenf/f (Lkb1d/dPtend/d)
mouse model that has accelerated LSCC development in 3 months
(Supplementary Fig. 3d–e; Supplementary Table 2; Supplemen-
tary Data 1−2 and 4), an incidence rate of lung adenosquamous
cell carcinomas (ASCs) at 88.9% (Supplementary Table 2 and
Supplementary Data 2), nearly identical molecular proﬁles
between lung SCC and ASC (Supplementary Fig. 3d−g), close
resemblance of the combined SCC/ASC transcriptome proﬁle
to that of human lung SCCs (Supplementary Fig. 3h and
Supplementary Data 3) and similar enriched upstream regulators
(Supplementary Table 3). In addition, epithelial hyperplasia
(11.1%) and epithelial hyperplasia with squamous metaplasia
(11.1%) were observed in the Lkb1d/dPtend/d mouse model
(Supplementary Data 1-2). Most importantly, JNK1/2 activities
were reduced in SCCs/ASCs (Fig. 2c, d and Supplementary
Fig. 4a). The pretumor stage of Lkb1d/dPtend/d mice was deﬁned
at 1 month old of age because at this time only hyperplasia was
found in the large airways (Supplementary Fig. 5a). A kinome
array assay revealed that reduced phosphorylation levels of
JNK1/2, ERK1/2 and p38α as well as increased AKT phosphor-
ylation occur in Lkb1d/dPtend/d lungs at the pretumor stage
(Fig. 2e; Table 3; Supplementary Fig. 4b–c and Supplementary
Table 5). The western blot assay validated that only P-JNK1/2
is consistently downregulated in both SCCs and ASCs and in
the pretumor stages (Fig. 2d and Supplementary Fig. 4c). The
reduced JNK1/2 phosphorylation in Lkb1d/dPtend/d mouse
hyperplastic epithelial cells was conﬁrmed by the IHC assay
(Fig. 2f). Histologically normal Lkb1-deﬁcient airways have
uniform p-JNK1/2, whereas hyperplastic lesions start to lose
p-JNK1/2 positivity (Fig. 2b, f). This suggests that the impact of
Lkb1 deletion on p-JNK1/2 levels does not appear to be entirely
direct, implying that proliferation induced by Lkb1 loss occurs
prior to the decline in p-JNK1/2 levels. The declined P-JNK1/2
levels may contribute to the development of hyperplastic lesions.
As a feedback regulation mechanism, these hyperplastic lesions
may facilitate the further decline of P-JNK1/2 by providing an
oncogenic environment. These ﬁndings show that JNK1/2
inactivation occurs before tumor formation.
Decreased MKK7 reduced JNK1/2 phosphorylation in mouse
LSCC. To investigate the underlying mechanism of JNK1/2
inactivation during LSCC development, we examined expression
levels of MKK7, which phosphorylates JNK1/2 at T183/Y185 to
regulate JNK1/2 activities in previous reports20,33,34. Both mRNA
and protein expressions of MKK7 were indeed decreased in
Lkb1d/d mouse LSCCs (Fig. 3a). The decrease of MKK7 expres-
sion occurs at the pretumor stage (Fig. 3b, c), sharing a similar
pattern with that of the decreasing JNK1/2 phosphorylation along
the course of LSCC development (Fig. 2c, f). Functionally,
MKK7’s impact on JNK1/2 phosphorylation in LSCC develop-
ment was assessed on a mouse LSCC cell line (mLSCC) that was
generated from LSCC tumors of Lkb1d/dPtend/d mice. Exogenous
expression of MKK7 in mLSCC by transfection restored JNK1/2
phosphorylation and decreased the levels of p63 and ΔNp63
(Fig. 3d, e). Similar results were observed in H157 cells, which are
human LSCC cells with the mutations of LKB1 and PTEN
(Supplementary Fig. 5c). Meanwhile, at the pretumor stage
modeled by a nontumorigenic human bronchial epithelial cell
line NL20 and Beas-2B, the MKK7 knockout also had reduced
JNK1/2 phosphorylation levels (Fig. 3g and Supplementary
Fig. 5e) while LKB1 ablation decreased levels of both MKK7
expression and phosphorylated JNK1/2 (Fig. 3f and Supplemen-
tary Fig. 5d). These results suggest that decreased MKK7
expression has a negative impact on JNK1/2 phosphorylation
levels during LSCC development. Furthermore, ablation of LKB1
and MKK7 in NL20 and Beas-2b promoted cell growth (Fig. 3h
and Supplementary Fig. 5f). These results not only delineate the
Table 1 Summary of mouse phenotypes of lung tumors and lungs
Genotype No. Age (Month) The percent (%) of phenotypes in mouse lungs
SCC-DS SCC SCC-DS+ SCC AD-DS AD AD-DS+AD
Lkb1d/d 56 11–14 25.0 16.1 32.8 16.1 37.5 53.6
Ptend/d 12 12–13 0 0 0 16.7 8.3 25.0
P53d/d 10 12–13 0 0 0 10.0 10.0 20.0
Mig6d/d 12 9 0 0 0 8.3 0 8.3
KrasG12D 8 1 0 0 0 100 37.5 100
Smad4d/d 9 11–13 0 0 0 0 0 0
WT 25 1–14 0 0 0 4.0 0 4.0
Lkb1d/d: CCSPiCre Lkb1f/f; Ptend/d: CCSPiCrePtenf/f; P53d/d: CCSPiCrep53f/f; Mig6d/d: CCSPiCreMig6f/f; KrasG12D: CCSPiCreKrasG12D; Smad4d/d: CCSPiCreSmad4f/f; WT wild type. SCC development stages
include epithelial hyperplasia, epithelial hyperplasia with squamous metaplasia, adenocarcinoma with squamous differentiation and adenosquamous carcinoma
Adenocarcinoma development stages include epithelial hyperplasia and adenoma
SCC squamous cell carcinoma, DS development stage, AD adenocarcinoma, No. number
Table 2 Analysis of enriched upstream regulators and its
core downstream pathways
Top upstream
regulators
P value of
overlap
Core downstream pathways
of TNF and IL1B
TGFB1 4.32E-41 JNK1/2 pathway
TNF 7.04E-39 p38 pathway
TP53 2.13E-28 NFĸB pathway
ERBB2 3.54E-26 ERK1/2 pathway
IL1B 7.85E-22
Top enriched upstream regulators were identiﬁed from these differentially expressed genes
identiﬁed in the microarray (13-month-old (13M) Lkb1d/d mouse lung SCCs vs. 13M Lkb1f/f
mouse lungs; Supplementary Data 3) using ingenuity pathway analysis (IPA)
SCC squamous cell carcinoma
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LKB1-MKK7-JNK1/2 pathway at the early phase of LSCC
development, but also establish a regulatory function of LKB1 on
the MKK7-JNK1/2 signaling that is regarded as a stress response
pathway in other systems.
Jnk1/2 loss accelerates Lkb1-null induced LSCC development.
Since the Lkb1-deﬁcient LSCC has a suppressed MKK7/JNK1/2
pathway and JNK1/2 have been indicated in tumor
formation24,34,35, we hypothesize that JNK1/2 plays a role in the
suppression of LSCC development. To test this, in vitro ablation
of Jnk1/2 was ﬁrst conducted in mLSCC cells to investigate its
effect on cellular activities. As anticipated, Jnk1/2 ablation
increased cell growth in mLSCC cells (Fig. 4a and Supplementary
Fig. 6a–b). The in vivo role of JNK1/2 in LSCC development
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Fig. 2 p-JNK1/2 are reduced in Lkb1-deﬁciency-driven mouse LSCC development. a Western blot (WB) analysis (n= 5) of protein expression in 13-month-old
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(n= 6). Black dashes point to the areas of interest. Box I: hyperplastic airway; Box II: adenocarcinoma (AD) component; Box III: peripheral squamous cell
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was next investigated by generating mice with the conditional
ablation of both Lkb1 and Jnk1/2 (Lkb1d/dJnk1d/dJnk2−/−)
(Supplementary Fig. 6c). Lkb1d/dJnk1d/dJnk2−/− mice started to
develop squamous metaplasia in the lungs at 4 months old, fol-
lowed by full penetrance of pathologic phenotypes (CK5+, P63+)
at 7 months old and beyond (Fig. 4b and Supplementary Fig. 6d).
The associated phenotypes include epithelial hyperplasia (66.7%)
(Fig. 4c), epithelial hyperplasia with squamous metaplasia (25%)
(Fig. 4b), and adenocarcinoma with squamous differentiation
(16.7%) (Supplementary Fig. 6e), ASC (25%) (Fig. 4d) and SCC
(33.3%) (Supplementary Fig. 6d) (Supplementary Data 1−2).
Compared to 11−14-month-old Lkb1d/d mice that showed epi-
thelial hyperplasia (5.4%) (Supplementary Fig. 1c–d), epithelial
hyperplasia with squamous metaplasia (1.8%) (Supplementary
Fig. 1e), squamous metaplasia (1.8%), adenocarcinoma with
squamous differentiation (10.7%) (Supplementary Fig. 1f),
ASC (5.4%) (Supplementary Fig. 1g), SCC (16.1%) (Fig. 1a, b)
(Supplementary Data 1−2), and loss of Jnk1/2 in the Lkb1-
deﬁcient background accelerated LSCC development in vivo.
Lkb1d/dJnk1d/dJnk2−/− mice also developed adenocarcinoma
(Supplementary Fig. 6f). Although the ADs generally showed a
papillary morphology microscopically, they resembled LSCCs in
that they are positive for IHC expression of the SCC markers
p63 and CK5 (Supplementary Fig. 6f). Interestingly, there is no
LSCC formation in Jnk1d/dJnk2−/− mice, which only has ade-
noma/adenocarcinoma development (33.3%) (Supplementary
Fig. 6g and Supplementary Data 1), concluding that the JNK1/2
pathway regulates LSCC development under a Lkb1-deﬁcient
background. These results suggest that Jnk1/2 knockout promotes
Lkb1-deﬁciency-induced SCC formation by inducing SCC marker
expression, such as p63. Taken together, these results reveal that
compound mutations of Jnk1/2 and Lkb1 facilitate LSCC devel-
opment and demonstrate that JNK1/2 act as major suppressors
for Lkb1-dependent LSCC progression.
JNK1/2 inactivation activates mouse LSCC ΔNp63/p63 path-
way. We next investigated the downstream effectors of JNK1/2 in
regulation of lung SCC development. ΔNp63 is a squamous cell
lineage marker promoting squamous cell stratiﬁcation and tumor
progression36,37. We had shown that ΔNp63 was induced in
hyperplastic airways and lung SCCs (Fig. 1b and Supplementary
Fig. 3f) and was not detected in mouse lung ADs (Supplementary
Fig. 1h and 2b). Based on the observation that expression patterns
were opposite between levels of ΔNp63 expression (Fig. 1b and
Supplementary Fig. 3f) and JNK1/2 phosphorylation (Fig. 2b, f)
during lung SCC development, we examined the effect of Jnk1/2
on the expression of ΔNp63. Jnk1/2 knockout mLSCC cells
exhibited an increase in ΔNp63 levels (Fig. 4e). Conversely,
treatment with stimuli of JNK1/2 pathway, IL-1β, TNFα or
Anisomycin raised JNK1/2 phosphorylation levels and decreased
the expression of ΔNp63 and p63 in parental or gRNA-Control
mLSCC cells (Fig. 4e)38. Quantiﬁcation of the protein bands
of ΔNp63 and p63 showed JNK1/2 had a stronger effect in
repressing ΔNp63 than inhibiting p63 expression (Fig. 4e and
Supplementary Table 6). Global assessment of the impact of Jnk1/
2 ablation on gene expression revealed increased P63 mRNA
levels, altered expression of downstream targets of TP63, and
changes in genes that are enriched for regulating cancer and cell
proliferation (Table 4; Supplementary Table 7 and Supplementary
Data 3). Downstream targets of TNF and IL-1β are also impacted
by Jnk1/2 ablation (Table 4 and Supplementary Data 3), which is
in accordance with the well-known role of JNK1/2 in mediating
activities of these two cytokines38–40. In summary, these results
indicate that JNK1/2 inactivation activates the ΔNp63/p63
pathway to promote LSCC development.
JNK1/2 activation attenuates mouse LSCC development. While
JNK1/2 activities were reduced in LSCC, JNK1/2 proteins remain
present in both tumor and pretumor stages of cells (Fig. 2a, b, d, f
and Supplementary Fig. 4c). This observation raises the question
whether manipulating JNK1/2 activities may have an impact on
Lkb1-dependent tumor formation. JNK1/2 activator Anisomycin-
treated mLSCC cells showed a signiﬁcant increase of JNK1/2
phosphorylation levels and the expression of apoptosis markers,
cleaved PARP and Caspase-3, whereas the JNK1/2 inhibitor
SP600125 reduced levels of these apoptotic indicators (Fig. 5a)38,41.
Less than 20% of mLSCC cells survived after Anisomycin treat-
ment, in contrast to the Jnk1/2 knockout signiﬁcantly maintaining
cell survival (Fig. 5b, c). Consistent with the in vitro results,
treatment of Lkb1d/dPtend/d mice with Anisomycin for 8 weeks
signiﬁcantly inhibited LSCC formation (Fig. 5d, e) and lung tumor
development (Supplementary Fig. 7), with no obvious inhibition
on lung adenoma/adenocarcinoma (Supplementary Data 1). In
contrast, Anisomycin did not affect the development of LSCC and
lung tumors in Lkb1d/dJnk1d/dJnk2−/− mice (Fig. 5f and Supple-
mentary Data 1). These ﬁndings demonstrate that raising JNK1/2
activities can inhibit LSCC cell growth in vitro and tumor pro-
gression in vivo, suggesting that targeting JNK1/2 may beneﬁt
LSCC patients who have low JNK1/2 activities.
JNK1/2 is inactivated in a large proportion of human LSCCs.
To further investigate the clinical relevance of JNK activities,
JNK1/2 phosphorylation levels were surveyed in the TCGA
protein array database30,42 and assayed using IHC in human lung
cancer tissue arrays. JNK1/2 phosphorylation levels in a sizable
proportion of human LSCCs was lower than the average level in
the TCGA protein array database, especially when compared to
human lung AD cases (Fig. 6a). Signiﬁcantly lower levels of
JNK1/2 phosphorylation in SCCs compared to normal airways
were also observed in two independent sets of human LSCC tissue
arrays (Fig. 6b–d and Supplementary Fig. 8a–b). In a subset of
patients, hyperplastic airway cells also exhibited lower levels of
JNK1/2 phosphorylation compared with normal airways (Fig. 6b
and Supplementary Fig. 8a–b), resembling the mouse phenotype
(Fig. 2b, c, f). In summary, JNK1/2 inactivation is present in a
substantial proportion of human LSCCs.
JNK1/2 activities predict survival rates of SCC patients. Gene
signature analysis of LSCC patients was then investigated to
determine whether JNK1/2 activities could predict patient sur-
vival. JNK1/2 activities were deﬁned by a gene signature that was
generated using these DEGs induced by knocking out Jnk1/2 in
mLSCC cells (Supplementary Data 3). Each TCGA human LSCC
patient’s JNK1/2 activities were estimated by applying mouse
Jnk1/2 knockout gene signatures to expression proﬁles of human
tumors43. Survival analysis showed that patients with higher
JNK1/2 activities in LSCC tumors had a better survival rate and
longer relapse-free survival (RFS) than those with lower JNK1/2
activities (Fig. 6e and Supplementary Fig. 8c-–d). In contrast,
Table 3 Top changed phosphorylated (P)-proteins in Lkb1d/
dPtend/d lungs (pretumor stage) compared to wild-type
(WT) lungs at 1 month of age
Top changed phosphorylated protein Change direction
① JNK pan (T183/Y185, T221/Y223) Down
② Erk1/2 (T202/Y204, T185/Y187) Down
③ P38α (T180/Y182) Down
④ AKT (S473) Up
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JNK1/2 activities were unable to predict the survival of lung
adenocarcinoma patients (Supplementary Fig. 8e–f). In con-
junction with the ﬁndings on JNK1/2 activities’ antitumor func-
tion in mice (Fig. 5), these results suggest a beneﬁcial effect of
increasing JNK1/2 signaling for treatment of human LSCCs.
Considering that JNK1/2 activation is required to induce cell
apoptosis in multiple SCC cells44–47, we generated the tissue-
speciﬁc JNK1/2 gene signature to predict the survival of other
human SCC patients. Notably, survival analysis showed that
the patients whose cervical or head and neck SCC tumors had
higher JNK1/2 activities had better survival rate than those
with lower JNK1/2 activities (Fig. 6f, g). These results suggest
that the JNK1/2 pathway is a conserved suppressor for SCC in
multiple tissues.
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Discussion
In this study, we generated a mouse lung SCC model in which the
sole ablation of Lkb1 in mouse lung airways is sufﬁcient to induce
LSCC and have established Lkb1 as a key suppressor gene of
LSCC. Lkb1 deﬁciency results in decreased expression of MKK7, a
reduction of JNK1/2 phosphorylation, lower JNK1/2 activities
and elevated ΔNp63 signaling, which subsequently leads to epi-
thelial cells transformation and progression into LSCC (Fig. 7).
Loss of Lkb1 however does not automatically cause loss of p-
JNK1/2 in normal mouse airway epithelial cells. This would
indicate that other events must occur to alter p-JNK1/2 levels.
However, even though p-JNK1/2 is lost during tumor progres-
sion, JNK1/2 protein levels are maintained. Therefore, JNK1/2
activities can still be stimulated at the tumor stage (Figs. 4e and
5a) and activation of JNK1/2 signaling may serve as a tool against
LSCC for both treatment and prevention.
Previous studies showed that simulation of LSCC in vivo had
only been successfully achieved by compound mutations,
including KrasG12D/Lkb1loss, Sox2OX/Lkb1loss, Ptenloss/Lkb1loss,
and Cdkn2aloss/Ptenloss/Sox2OX8–11. Although Lkb1 is involved
in three of these mouse models, ablating Lkb1 alone using
adenovirus-Cre (Ad-Cre) fails to cause pulmonary neoplasia9. As
a result, Pten loss or Sox2 overexpression was given more weight
as the major factors in driving LSCC development. Since the
efﬁciency and accuracy of delivering Cre recombinase intranasally
and intratracheally remain uncertain27,48, ﬁndings based on this
method may be limited in scope due to technical challenges,
especially for pathogenesis in the mouse large airways where
human LSCC is frequently initiated5. On the contrary, CCSPiCre
is a proven efﬁcient Cre driver that mediates the loxP-dependent
DNA recombination in all airway epithelial cells including the
large airways13,49. Results based on the CCSPiCre system indeed
revealed a previously underestimated role of Lkb1 lost-of-
function mutation that by itself Lkb1 deﬁciency is sufﬁcient to
initiate LSCC, in comparison with any single mutation in either
Trp53, Pten, Errﬁ1, Smad4 or KrasG12D (Table 1)10,12–14. Fur-
thermore, the merit that Lkb1 ablation alone induces LSCC offers
a simpliﬁed platform for screening other regulators of LSCC
development. These observations not only place Lkb1 in its right
place of the LSCC driving formula, but also show that the
CCSPiCreLkb1f/f model is a valuable tool for further investigating
additional players that contribute to LSCC development.
In the CCSPiCreLkb1f/f model, LSCC and lung adenocarcinoma
were formed at different locations of mouse lung. LSCCs were
usually located in the central part of the lung (Fig. 1a and Sup-
plementary Fig. 1c), close to the trachea, after the deletion of Lkb1
in large airways (Supplementary Figs. 1a–b and 5a–b). In con-
trast, lung adenocarcinomas were often found in the distal parts
of CCSPiCreLkb1f/f mouse lung (Supplementary Fig. 2a). This is
consistent with human LSCC that belongs to central lung neo-
plasm50 and is frequently initiated from large airways5. Taken
together, our CCSPiCre mouse can be an efﬁcient model for the
in vivo study of lung diseases initiated from large airway and of
the de novo role of these frequently mutated genes.
JNK1/2 inactivation is associated with not only LSCC but also
cervical and head and neck SCC (Fig. 6), suggesting a conserved
role of JNK1/2 in various types of SCC development. JNK1/2
activation is required to induce cell apoptosis in multiple SCC
cells, including esophageal, oral, head and neck and cervical SCC
cells44–47. These results suggest that JNK1/2 inactivation in vivo
may promote or lead to SCC formation and progression besides
lung SCC. A recent in vivo example is the off-target actions
of BRAF inhibitors. They were used for inhibiting melanoma
growth, but at the same time also promoted squamous cell car-
cinoma development that has been reported due to JNK pathway
inhibition51. In addition to lung SCCs, LKB1 and MKK7, as
upstream regulators of P-JNK1/2, are also found to be frequently
mutated in other human SCCs, such as cervical, cutaneous, head
and neck and esophageal SCCs (cBioPortal databases)52,53.
Meanwhile, we showed that the ΔNp63 pathway, a well-proven
oncogenic and squamous linage pathway36, was activated after
JNK1/2 inactivation. This further suggests that JNK1/2 inactiva-
tion promotes SCC development through a common downstream
target p63 since TP63 was also ampliﬁed in human cervical and
head and neck SCCs (cBioPortal databases). In summary, JNK1/2
pathway may act as a conserved gatekeeper preventing the
development of SCCs.
Current targeted therapies for LSCC are limited because the key
drivers have not been identiﬁed. Although the Ikka mutant
(K44A) knock-in mice does develop spontaneous LSCCs54, K44A
mutation has not been identiﬁed in human LSCC, and the copy
number losses and other genomic mutations in IKKa are also rare
in human LSCCs7. Here, we demonstrated the potential to target
JNK1/2 for human SCC treatment in preclinical models in that
activation of P-JNK1/2 using Anisomycin induced LSCC cell
death and inhibited LSCC development (Fig. 5). Anisomycin, a
natural product produced by some Streptomyces bacteria,
Fig. 3 Decreased MKK7 in response to Lkb1 deﬁciency reduces JNK1/2 activities. a qRT-PCR (upper panel) and WB (lower panel) analyses of the mRNA
and protein expression of MKK7 in mouse lungs and lung SCCs, respectively (n= 5). Error bar is SEM; T test: *P < 0.05. b Representative IHC staining of
MKK7 in 1-month-old mouse lungs (n= 5). Black dashes point to the areas of interest. Scale bar: 10 μm. c Representative IHC staining results of MKK7 in
3-month-old mouse lungs and lung tumors (n= 6). Black dashes point to the areas of interest. Box I: hyperplastic airway; Box II: adenocarcinoma (AD)
component; Box III: peripheral squamous cell carcinoma (SCC) component. Scale bar: 300 μm (black box) and 10 μm (dark bar). d WB analysis of protein
expressions in mouse lung SCC cells (mLSCCLP.3). e Co-staining of Flag/MKK7 and pJNK1/2 or p63 or ΔNp63 in mouse LSCC cells. Scale bar: 50 μm;
Yellow arrows point out the cells expressing the exogenous Flag-MKK7; white arrows point out the cells without clear expression of the exogenous Flag-
MKK7. f WB analysis of protein expressions in NL20 cells, an immortalized human bronchial epithelial cell line, after knockout of LKB1 or scramble
(Control) using lentiviral Cas9/gRNA with the treatment of TNFα (20 ng/mL). gWB analysis of protein expressions in NL20 cells after knockout of MKK7
or scramble (Control) using lentiviral Cas9/gRNA under 5-h treatment of TNFα (20 ng/mL). h MTS assay analysis of cell viability of NL20. −: parental
cells; gControl: gRNA targeting noncoding region; gLKB1: gRNA targeting LKB1; gMKK7: gRNA targeting MKK7
Table 4 Ingenuity pathway analysis (IPA) of the
differentially expressed genes after knockout Jnk1/2 in
MSCCLP.3 cells (Supplementary Data 3)
P value
Top diseases
Cancer 2.25E-06–5.73E-19
Top cellular function
Cellular growth and proliferation 2.25E-06–2.12E-28
Cell death and survival 2.25E-06–3.84E-26
Enriched upstream regulators
TNF 1.26E-30
TP63 8.77E-20
IL1B 2.33E-18
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09843-1
8 NATURE COMMUNICATIONS |         (2019) 10:2148 | https://doi.org/10.1038/s41467-019-09843-1 | www.nature.com/naturecommunications
stimulates JNK1/2 phosphorylation55. Clinically, Anisomycin has
been successfully used for the treatment of amoebic dysentery and
trichomoniasis55. It also sensitizes tumor cells to apoptosis
induced by the TNF-related apoptosis-inducing ligand (TRAIL)56.
The observation that JNK1/2 activities positively correlate with
the survival rates of multiple types of SCC patients suggests
application of JNK1/2 activators, such as Anisomycin or its deri-
vatives could be an option for SCC patients with low JNK1/2
activities.
Drugs targeting JNK1/2 that are currently under clinical trial
or FDA-approved for the treatment of other cancers could
be investigated for their anticancer effects on LSCCs. For
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example, Genistein, which is an enzyme inhibitor and in clinical
trial, has been showed to have antitumor effects in human
hepatocellular carcinoma cells and to activate JNK1/2 57. In
addition, 2-methoxyestradiol, which belongs to mitosis mod-
ulators and is also in clinical trial, induced apoptosis in prostate
cancer cells through the activation of P-JNK1/258. Therefore,
repurposing existing drugs to activate JNK1/2 for LSCC treatment
is possible.
Although epithelial hyperplasia and squamous metaplasia are
regarded as the initial stages of human LSCC5, not much was
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described in previous in vivo models4,11. Hence, the mechanism
of LSCC formation and progression regulated by genetic alter-
nations are largely unknown. Our work documented tumor
progression at the stages of epithelial hyperplasia and squamous
metaplasia with different clinical markers as well as provided
underlying mechanisms that contribute to pathogenesis. First, we
observed epithelial hyperplasia with squamous metaplasia had
positive expression of p63 and CK5 in Lkb1d/d (Supplementary
Fig. 1e) and in Lkb1d/dJnk1d/dJnk2−/− (Fig. 4b) mice, but both
epithelial hyperplasia and adenomas had negative expression
of p63 and CK5 in KrasG12D mice (Supplementary Fig. 2f).
Consistent with the observations in human lung cancers, these
mouse results show that epithelial hyperplasia can develop into
SCC, AD or ASC, and the developmental direction of epithelial
hyperplasia can be reﬂected by expression of these markers,
such as p63 and CK5 for SCC and TTF1 for AD. In the ASCs, the
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JNK1/2 in TCGA human lung cancer cohorts (SCC.1, n= 159; SCC.2a, n= 38; SCC.2b, n= 88; AD.1, n= 94; AD.2, n= 68; AD.3, n= 75; AD.4, n= 90;
AD.5a, n= 25; AD.5b, n= 49). b, c Representative IHC staining (b) and the semi-quantiﬁcation (c) of P-JNK1/2 in a human LSCC tissue array. The
quantiﬁcations were calculated with DAB staining density (brown color) using ImageJ. Optical Density (OD)= log (max intensity/Mean intensity). Two
random equal regions of each patient were quantiﬁed for SCC (70 patients), and 30 normal airway regions (eight patients) and eight hyperplastic airways
(four patients) were quantiﬁed. ANOVA (TKMC test) was performed and the error bar is SEM; ***P < 0.001. Arrows (left panel): Weak nuclear staining;
Scale bar: 10 μm. d Semi-quantiﬁcation of a tissue array was calculated with DAB staining density (brown color) as described in (c); three random equal
regions of each patient were quantiﬁed, including SCC (21 patients), the matched normal airway (21 patients) and the hyperplastic airways (18 patients).
ANOVA (TKMC Test) was performed and the error bar is SEM; *P < 0.05; ***P < 0.001. e Prediction of human LSCC patient survival rate using Jnk1/2
knockout mouse signature. The gene signature was generated using the DEGs identiﬁed after knockout of Jnk1/2 in MSCCLP.3 cells (Supplementary
Data 3). High JNK1/2 activities were deﬁned as patient gene signature scores lower than 0 and vice versa. Each small bar of curve line represents one
patient and T test was performed. If the score was below 0, JNK1/2 activities were considered high, and vice versa. f, g Higher JNK1/2 activities are
associated with longer survival rate of cervical and head and neck SCC patients. The method was as described in (e) and Methods
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portions of tumors consisting of AD cells also exhibited the same
marker expression of SCC cells (p63 and CK5) in Lkb1d/d
(Supplementary Fig. 1g), in Lkb1d/dPtend/d (Supplementary
Fig. 3e) and in Lkb1d/dJnk1d/dJnk2−/− (Fig. 4d) mice. Meanwhile,
ASC’s molecular proﬁles are almost identical to that of SCC
(Supplementary Fig. 3g). Therefore, the clinical marker staining,
such as p63 and CK559, can predict the developing tract before
the formation of these typical pathological phenotypes. Second,
Lkb1d/d, Lkb1d/dJnk1d/dJnk2−/− and Lkb1d/dPtend/d mouse
models in our study can recapitulate the different LSCC devel-
opmental stages (DSs) (Fig. 4b–d; Supplementary Figs. 1d–g and
3d–e; Supplementary Data 1−2). This offers the possibility of
systematically analyzing the dynamic changes of molecules dur-
ing LSCC development and to identify these genetic “gatekeepers”
of LSCC progression in vivo. We observed that the down-
regulation of P-JNK1/2 was associated with the progression of
LSCC in Lkb1d/d and Lkb1d/dPtend/d mice. As we described in
Table 5, Jnk1/2 knockout under Lkb1-loss background not only
shortened the average developing time of LSCC-DSs from
13 months to 4 months, but also increased the incidence of
LSCC-DSs from 25 to 100%, besides the promotion of LSCCs.
Unlike Lkb1d/d mouse lungs in which only some of epithelial
hyperplasia were positive for staining of p63 and CK5 (Supple-
mentary Fig. 1c–d and Supplementary Data 2), they can be
detected in all epithelial hyperplasia of Lkb1d/dJnk1d/dJnk2−/−
mouse lungs (Fig. 4b, c and Supplementary Data 2). Furthermore,
some of lung adenocarcinoma in Lkb1d/dJnk1d/dJnk2−/− mice
showed p63 and CK5 positive staining (Supplementary Fig. 6f).
These results conclude that JNK1/2 inactivation drives LSCC
formation and development in response to Lkb1 deﬁciency.
Therefore, evaluation of LSC-DSs can facilitate studying what and
how genetic elements regulate LSCC development.
Investigation of how JNK1/2 signaling inhibits ΔNp63
expression helps further dissect the mechanism of JNK1/2
repressing LSCC development. One potential link between
JNK1/2 and ΔNp63 is c-Jun. ΔNp63 has been reported to be
negatively regulated by c-Jun in response to Amyloid-β-
Induced cell stress60 while JNK1/2 is a typical activator of c-
Jun34. Interestingly, our microarray analysis of SCCs in Lkb1d/d
and Lkb1d/dPtend/d mice showed that c-Jun expression is sig-
niﬁcantly decreased (Supplementary Data 3). We also observed
the signiﬁcant reduction of c-Jun in a Jnk1/2 knockout array
(gRNA-Jnk1/2 vs. gRNA-Control) (Supplementary Data 3).
These results suggest inactivation of the JNK1/2 pathway induces
ΔNp63 expression partially due to the decrease of c-Jun. Con-
tinued identiﬁcation of the pathways regulated by JNK1/2 will
serve to better target and customize therapy for SCC.
The LSCC model resulting from Lkb1 loss in the pulmonary
epithelium represents a model to study the cellular origins of
SCCs. Anatomic location precursors suggest that SCCs in our
mouse model arise de novo (Figs. 1b and 4b; Supplementary
Fig. 1c-e and Supplementary Data 2). Our CCSPiCre has been
shown to have Cre activity in the basal cells of the proximal
airway13, which are p63-positive and are generally thought to be
one of the main cellular origins11. This suggests that some of SCC
cells were developed from these p63-positive basal cells. The
observation of SCC only in Lkb1d/d (8.9%), Lkb1d/dPtend/d
(11.1%) and Lkb1d/dJnk1d/dJnk2−/− (16.7%) mice also supports
this idea (Supplementary Data 1-2). Here, we deﬁned the mice
of SCC only as the ones that have only SCC lesions and non-
adenocarcinoma precursors. Meanwhile, SCCs may also trans-
differentiate from adenocarcinoma or its precursors. This idea
was indicated by the SCC marker staining (CK5 and P63), which
was positive in SCC-DSs of these models (Supplementary
Figs. 1f–g, 3e and 6e–f; Fig. 4c, d and Supplementary Data 2),
especially for these adenocarcinoma precursors. Considering
the reports of the trans-differentiation from Lkb1-deﬁcient ade-
nocarcinoma (AD) into SCC in Ad-Cre-KrasG12DLkb1f/f
mice37,61,62, this possibility also exists. The use of single-cell
RNA-Seq tumors for this model at varying stages of development
will help identify the changes in cell types and the transcriptome
of these cells during SCC progression. This will aid in under-
standing the cellular origins of SCC.
Interestingly, the COSMIC database (https://cancer.sanger.ac.
uk/cosmic), which includes 1588 SCC and 36 ASC samples
among 8018 patients, shows that the frequency of LKB1 muta-
tions in pure human SCC and ASC is 1.89% and 11.11%,
respectively. In other words, the mutation rate in ASC is much
higher (5.89 fold) than SCC. Therefore, LKB1 may require sec-
ondary mutations, such as PTEN or alterations in JNK1/2 sig-
naling to direct the progression of the de novo tumors to SCC vs.
ASC or to promote the progression of ASC to SCC. Meanwhile,
we observed one common mutation (CDS: c.1062C > G; AA: p.
F354L) between SCC and ASC, which may indicate the potential
for transdifferentiating.
In summary, we exploited the experimental merits of the
mouse to establish Lkb1 as a key driver gene from those fre-
quently mutated genes in human LSCCs, and to understand the
formation and progression of LSCC by unveiling the de novo
role of JNK1/2 inactivation. Extending the ﬁnding of JNK1/2
Lkb1–/–
P-JNK1/2 P-JNK1/2
ΔNp63ΔNp63
MKK7
LSCC
Mature LSCCNormal airways Hyperplasticairways
Squamous
metaplasia
Fig. 7 Working model. Lkb1 loss in airways decreases MKK7 expression
levels, reduces JNK1/2 phosphorylation levels and activities, and de-
represses oncogenic and squamous linage pathway(s) (e.g. ΔNp63
pathway), which prompts hyperplasia and squamous metaplasia in normal
airway cells, breaks the barrier against LSCC formation, and promotes LSCC
development
Table 5 Summary of Lkb1d/dJnk1d/dJnk2−/− mouse lung tumor phenotypes in comparison to Lkb1d/d mouse lung tumor
phenotypes
Genotype No. Age (Month) The percent (%) of phenotypes in mouse lungs
SCC-DS SCC SCC-DS+ SCC AD-DS AD AD-DS+AD
Lkb1d/d 56 11–14 25.0 16.1 32.8 16.1 37.5 53.6
Lkb1d/dJnk1d/dJnk2−/− 12 7–8 100 33.3 100 8.3 33.3 33.3
SCC squamous cell carcinoma, DS development stage, AD adenocarcinoma, No. number
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from mice to human shows that JNK1/2 is inactivated in a large
population of LSCCs and its activity is positively associated with
longer survival rate of multiple human SCC patients, including
LSCC. Our model-informed progression analysis, together with
genetic, functional and clinical relevance studies, establishes
JNK1/2 as a key regulator of LSCC progression in mice and
humans, providing a promising target for the therapy of SCC
patients with low JNK1/2 activities, including LSCCs.
Methods
Mice. CCSPiCre and Mig6f/f mouse strains were made by Dr. DeMayo’s lab and
Jnk1f/fJnk2−/− mouse strain was made by Dr. Roger Davis’s lab and the generation
methods of these mice were in previous publications13,63,64. Lkb1f/f (FVB;129S6-
Stk11tm1Rdp/Nci), KrasG12D (B6.129-Krastm4Tyj/Nci) and p53f/f (FVB.129P2-
Trp53tm1Brn/Nci) mouse strains were from the NCI Frederick Mouse Repository.
Ptenf/f (C;129S4-Ptentm1Hwu/J) strain were from Jackson Lab. Smad4f/f (Sma-
d4RobCA) stain is from Dr. Elizabeth J. Robertson’s lab. The deletion or over-
expression of those genes in mouse lung was achieved by breeding conditional
genetic mice with CCSPiCre mice. All animal protocols were approved by the
National Institute of Environmental Health Sciences and Baylor College of Med-
icine. All experiments were conducted in accordance with relevant guidelines and
regulations of both institutions. All strains were B6;129 and all mice were geno-
typed by Transnetyx. Similar numbers of female and male mice were purposely
included in all the mouse experiments, and no histopathologic differences were
observed between female mice and male mice during lung tumor development.
Anisomycin treatment. WT (Lkb1f/fPtenf/f) and Lkb1d/dPtend/d (CCSPiCreLkb1f/
fPtenf/f) mice at 6 weeks old received Anisomycin (SIGMA, A9789) or vehicle
through intraperitoneal (i.p.) injection for 8 weeks65,66. Anisomycin was dissolved
in DMSO and diluted in PBS, and the ﬁnal dissolved reagent was constituted by
7.5% DMSO and 92.5% PBS, which served as the vehicle. Two concentrations
(0.5 mg/kg and 2.5 mg/kg) of Anisomycin were used for treatment three times per
week67. Similarly, Lkb1d/dJnk1d/d Jnk2−/− (CCSPiCreLkb1f/fJnk1f/fJnk2−/−) mice
at 6–7 months old received Anisomycin (2.5 mg/kg) or vehicle through intraper-
itoneal (i.p.) injection for 8 weeks. Fifty microliters was used per injection. Two
hours after the last treatment, mice were euthanized for tissue collection and
examination of lung.
Cell derivation and culture. mLSCCLP.3 cells were isolated from Lkb1d/dPtend/d
mouse lung SCC tumors using a cancer cell isolation kit as per the protocol. NL-20,
Beas-2B and H157 cells were purchased from ATCC. The culture medium for
MSCCLP.3 cells included RPMI, 10% FBS, penicillin (100 IU/mL) and streptomycin
(100 μg/mL). NL20 was cultured using complete growth medium: Ham’s F12
medium, 2.7 g/L glucose, 0.005 mg/mL insulin, 10 ng/mL epidermal growth factor,
0.001 mg/mL transferrin, 500 ng/mL hydrocortisone and 4% FBS. Beas-2B was
cultured using the BEGM kit (Lonza, No. CC-3170). H157 cells was cultured using
DMEM and 10% FBS, penicillin (100 IU/mL) and streptomycin (100 μg/mL).
Given that P-JNK1/2 in lung SCC tumors of Lkb1d/dPtend/d mice was low (Fig. 2c,
d), TNFα or IL-1β was used to treat mLSCC cells. Before the treatment of TNFα or
IL-1β, the cells were starved with free medium overnight. The free medium means
RPMI for mLSCCLP.3 cells or Ham’s F12 medium for NL20 cells or BEBM medium
for Beas-2B cells. As described in the American Type Culture Collection (ATCC),
an NL20 cell is an immortalized and nontumorigenic human bronchial epithelial
cell line that was established by expression of replication-defective SV40 large T
antigen, and Beas-2B cells were isolated from normal human bronchial epithelium
obtained from the autopsy of noncancerous individuals and infected with an
adenovirus 12-SV40 virus hybrid (Ad12SV40) and cloned. H157 cells are human
LSCC cells with mutations of LKB1 and PTEN.
Plasmid transfection. Flag-MKK7 and Flag-pcDNA3.1 were purchased from
Addgene. Both plasmids were transfected into mLSCCLP.3 and H157 cells following
the manufacturer protocol of Lipofectamine 2000. Western blot and immuno-
ﬂuorescence (IF) were performed to examine the transfected cells after transfection
for 48 h using the similar methods68. Details of IF staining process: 1. Place cells on
12 mm coverslips in 24-well plates (Fisher-12-545-82-12cir-1D); 2. Wash cells
twice using 1× PBS (pH 7.4); 3. Fix cells in 0.5 mL 4% paraformaldehyde (10 mL
16% in 30 mL PBS) (polysciences, Inc. # 18814) for 10 min at RT; 4. Wash cells
twice using 1× PBS (pH 7.4); 5. Incubate cells in 0.5 mL 0.5% Triton-X-100 in PBS
for 5 min at RT; 6. Wash cells twice using 1× PBST (PBS with 0.2% Tween 20, pH
7.4); 7. Prepare blocking buffer using 1× PBST with 5% normal donkey serum
(Jackson Immune Research 017-000-121) plus 0.2% Fish Stain Gelatin (leave at 37 °
C to dissolve), and incubate cells in blocking buffer 60 min at room temperature
(RT); 8. Incubate cells using primary antibodies for overnight at 4 °C, which is
diluted in blocking buffer (1:100–1:1000); 9. Wash cells three times using 1× PBST
5min each at RT; 10. Incubate cells using secondary Ab for 60 min at RT, which
was diluted in blocking buffer (1:200); 11. Wash cells three times using 1× PBST 5
min each at RT; 12. Place cells on slide using Vectashield Mounting Media (H1500,
Hardset); 13. IF pictures were taken using confocal microscopy.
Cell proliferation, colony and survival assay. For cell proliferation assay, ~2000
NL20 and Beas-2B cells were seeded in one well in a 96-well plate at day 0,
respectively. Each group has four replicates. Each assay was performed by adding
20 μL MTS reagent (Promega, #G3582) into each well containing 200 μL cell cul-
ture medium, incubating for 1 h and then recording absorbance at 490 nm with a
96-well plate reader. mLSCCLP.3 cells were cultured in six-well plates and each
experiment group included six wells for colony and survival assay. For cell colony
assay, ~10,000 cells were seeded at day 0. For the survival assay, ~1 × 105 cells were
seeded at day 0. At the endpoint of experiments, cells were washed one time using
1× PBS and then ﬁxed by 3.7% paraformaldehyde (PFA) for 15 min at room
temperature (RT). PFA was removed and the cells were stained for 30 min with
0.05% Crystal Violet69. Cells were gently washed ﬁve times using tap water. Plates
were drained by inverting them overnight, and each well was photographed. The
stained cells were counted based on the photo using ImageJ method70.
Histopathology and immunohistochemistry. The experiments were performed
following the similar methods8,17. Mouse lungs were ﬁxed in 4% paraformaldehyde
and parafﬁn-embedded according to standard protocols. H&E and IHC analyses
were performed on 5 μm lung sections. Sections underwent dewaxing using
CitriSolv clearing agent followed by antigen retrieval and peroxide quenching with
3% H2O2 in methanol for 15 min and blocked with 5% normal goat serum plus
Avidin (four drops of Avidin from Avidin/Biotin Blocking Kit/mL) or MOM
blocking reagents at RT for 1 h. Subsequently, the slides were incubated with
primary antibodies diluted in 5% normal goat serum plus Biotin (four drops of
Biotin from Avidin/Biotin Blocking Kit/mL) at 4 °C overnight. Slides were washed
using 1× PBS ﬁve times (5 min per time), and then incubated with 1% BSA to block
at RT for 30 min and then followed with secondary antibodies diluted in 1% BSA at
RT for 30 min. The slides were then developed using the Vectastain ABC kit and
DAB reagents. The subgroups of different proteins from the same staining slide
(e.g., four H&E groups (Supplementary Fig. 1d) are indicated in the large area
(Supplementary Fig. 1c). All H&E and IHC results were scanned at the NIEHS
Image Core, including the tissue array slides. Scanning method: 1. Slides were
cleaned with an isopropanol solution prior to scanning. 2. Slides were then scanned
using the Aperio AT2 Scanner, (Aperio: Leica Biosystems Inc., Buffalo Grove, IL).
This machine uses line scanning technology to capture high-resolution, seamless
digital images of glass slides. 3. After scanning, slides were viewed and captured
using Aperio ImageScope v. 12.3.0.5056 (Aperio: Leica Biosystems Inc., Buffalo
Grove, IL), a digital slide viewing program. Measurements were taken from these
images using a measurement scale that was internally calibrated for each image as it
was scanned. p63 and ΔNp63 and TTF1 are nuclear staining and multifocal.
Squamous cell carcinomas showed positive staining of both P63 and ΔNp63.
Within the SCCs, the compact arrangements of basal-appearing cells with scant
cytoplasm tended to show nuclear staining of p63.
Human tissue array. The array samples shown in Fig. 6b, c and Supplementary
Fig. 8a were purchased from US Biolab. The detailed patient information can be
downloaded from US Biolab website. And the other batches of array (Fig. 6d and
Supplementary Fig. 8b) were from the Pathology and Histology Core at Baylor
College of Medicine. Histological examinations were conﬁrmed by Dr. Patricia D.
Castro and Dr. Michael M. Ittmann. The detailed patient information can be found
in Supplementary Table 8. The full staining slides were scanned at the NIEHS
Image Core as described in the paragraph of Histopathology and IHC, and random
regions of each patient were quantiﬁed using the optical density (OD) values,
which were calculated based on the DAB staining density (brown color) using
ImageJ17. OD= log (max intensity/mean intensity). ANOVA (TKMC Test) was
performed.
Microarray and ingenuity pathway analysis. RNA isolation: Following the same
RNA isolation protocol8, total RNAs were isolated from mouse lungs or lung
tumors using TRIzol reagent and cleaned by RNeasy kit. For mouse cells, total
RNAs were isolated by RNeasy kit. All mRNAs were reversely transcribed into
cDNA with the M-MLV kit. RNA quality was assessed by using the Agilent Model
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Experiment processes: (1) GSE111313 and GSE111314 arrays were performed at
NIEHS. Gene expression analysis was conducted using Agilent Whole Mouse
Genome 4 × 44 multiplex format oligo arrays (Agilent Technologies, 014868)
following the Agilent one-color microarray-based gene expression analysis
protocol. Starting with 400 ng of total RNA, Cy3-labeled cRNA was produced
following the manufacturer’s protocol. For each sample, 1.65 μg of Cy3-labeled
cRNAs was fragmented and hybridized for 17 h in a rotating hybridization oven.
Slides were washed and then scanned with an Agilent Scanner. Data were obtained
using the Agilent Feature Extraction software (v12), using the one-color defaults
for all parameters. The Agilent Feature Extraction Software performed error
modeling, adjusting for additive and multiplicative noise. The resulting data were
processed using OmicSoft Array Studio (Version 10) software. (2) GSE111335 was
performed at BCM using SurePrint G3 Mouse GE 8 × 60 K Microarray Kit: The
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Genomic and RNA Proﬁling Core ﬁrst conducted Sample Quality checks using the
NanoDrop ND-1000 and Agilent Bioanalyzer. Agilent One-Color Expression-Low
Input Quick Amp v6.6 (Sept 2012) protocol was followed.
Labeling protocol: Fifty nanograms of total RNA, combined with RNA spike
mix, were reverse transcribed using a T7 Primer Mix to produce cDNA. The cDNA
product was transcribed using T7 RNA Polymerase, producing cyanine-3-labeled
cRNA. The labeled cRNA was puriﬁed using a Qiagen RNeasy Mini Kit. Puriﬁed
products were quantiﬁed using the NanoDrop spectrophotometer for yield and dye
incorporation and tested for integrity on the Agilent Bioanalyzer. Six hundred
nanograms of the labeled cRNA was fragmented.
Hybridization protocol: Approximately 480 ng of fragmented cRNA samples
was loaded onto each of the Mouse G3 8 × 60 K Expression arrays. The arrays were
hybridized in an Agilent Hybridization Chamber for 17 h at 65 °C with rotation at
10 rpm.
Wash protocol: The arrays were washed using the Agilent Expression Wash
Buffers One and Two, followed by acetonitrile, as per the Agilent protocol.
Scan protocol: Once dry, the slides were scanned with the Agilent Scanner
(G2565BA) using Scanner Version C and Scan Control software version A.8.3.1.
Data extraction and quality assessment of the microarray data was completed using
Agilent Feature Extraction Software Version 11.0.1.1.
Expression array analysis: The ﬁles with raw expression value were used to
identify differentially expressed genes (DEGs) by the Genomics Suite Gene
Expression workﬂow of Partek software package version 6.6 (Partek Inc., St. Louis,
MO, USA). The quantile normalization and log2 transformation were applied to
generate signal values of all samples. The expression proﬁles were compared among
different groups using a one-way ANOVA model, and all the DEGs are listed in
Supplementary Data 3.
Functional analysis: Functional analysis of DEGs was performed using the
Ingenuity Pathway Analysis (IPA, www.ingenuity.com) based on the content of
2015-03-22. For a given biological category in IPA, Fisher’s exact test was used to
calculate the P value. The categories with P values less than 0.05 were deﬁned as
signiﬁcantly enriched. Microarray data were deposited in the Gene Expression
Omnibus (GEO, accession GSE111313, GSE111314 and GSE111335).
Real-time quantitative PCR and western blotting (WB). These experiments
were done using the same conditions8,17. Brieﬂy, lung tissues were stored at −80 °C
and total RNA was extracted using the TRIzol method followed by puriﬁcation
using an RNeasy Mini Kit. RNA quality was assessed by using the Agilent
Model 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Total RNAs
were reverse transcribed into cDNA with the M-MLV kit following the protocol.
The list of primers for SYBR® Green is shown in Supplementary Table 9. The
Taqman probes for 18s (4310893E) and Lkb1 (Mm00488470_m1) were
purchased from Applied Biosystems. Full blots of key ﬁgures can be found in
Supplementary Fig. 9.
Kinome array. The kinome array was purchased from R&D Systems (Cat. no.:
ARY003B), which can simultaneously detect the relative site-speciﬁc phosphor-
ylation of 43 kinases and 2 related total proteins. Each experiment group (Sup-
plementary Fig. 4b-c and Supplementary Table 5) included six mouse lungs (~15
mg per mouse). Lungs were combined and homogenized to extract proteins. The
remainder of the steps followed the standard protocol of the array kit. Non-
saturated dots in the membrane were quantiﬁed using ImageJ13 and normalized in
the other groups to WT group (Lkb1f/f Ptenf/f mouse lungs).
Cas9/gRNA experiments. The gRNA sequences are included in Supplementary
Table 9. These gRNAs were cloned into the LentiCRISPRv2 vector63. CRISPR-
Lenti nontargeting control plasmid was purchased from MilliporeSigma (Billerica,
MA) (CRISPR12-1EA). MAX Efﬁciency DH5α (ThermoFisher Scientiﬁc, Cat#
18258012) were used to amplify plasmids. Lentiviruses were produced in the Viral
Vector Core Laboratory of NIH/NIEHS or Baylor College of Medicine and were
used to infect cells for the knockout of the speciﬁc gene. The pooled cells infected
by gRNA were collected for western blot to conﬁrm the knockout efﬁciency.
Noninfected and gRNA-control-infected cells were used as controls.
Gene signature analysis. The gene expression array dataset GSE11969 (Takeuchi
et al., 2006) was analyzed with the mouse lung cancer gene signature approach13.
The publicly available datasets of human SCC (n= 553), AD (n= 576), head and
neck SCC (n= 566), and cervical SCC (n= 308) cohorts were downloaded from
the UCSC Xena webpage (https://xenabrowser.net/hub/). The mean-normalized
gene and protein expression values were used for further analyses. The patient
phenotype included survival time (OS) and longer relapse-free survival (RFS). The
gene expression proﬁle of each human sample was scored based on Jnk1/2 sig-
nature, which was generated from the mouse Jnk1/2 knockout model using our
previous published method43. For the head and neck SCC, and cervical SCC
datasets, only the genes passing expression cutoff ﬁlter of average FPKM (Frag-
ments Per Kilobase Million) higher than 5 are included in the analysis. The gene
signature score (also known as a “t-score”) was deﬁned for each sample as the two-
sided t statistic comparison of the high Jnk1/2-signature genes’ expression proﬁle
with the low Jnk1/2-signature genes’ proﬁle. Samples with a gene signature score (t-
score) higher than 0, which share a similar gene signature proﬁle of Jnk1/2
knockout in mLSCCLP.3 cells, were classiﬁed as having low JNK1/2 activities and
vice versa.
Gene set enrichment analysis (GSEA). The oncogenic signatures (c6.all.v6.1.
symbols.gmt) of the GSEA 3.0 version were used. All detected genes were pre-
ranked based on their fold changes (SCC vs. WT) from high to low (Supplementary
Data 3). The settings of GSEA were listed: Number of permutations (1000),
Enrichment statistic (Classic), Normalization mode (Meandiv), Make detailed gene
set report (True) and Seed for permutation (Timestamp).
Quantiﬁcation and statistical analysis. Data are expressed as mean+ SD or
mean+ SEM. The sample size (n) represents biological replicates. Student’s t test
was used for comparison of two group averages. When there were more than two
groups, one-way ANOVA Tukey−Kramer multiple comparisons (TKMC) test was
performed. GraphPad Prism version 7.02 was used to generate the survival curves
and calculate the P value of log-rank (Mantel−Cox) test. Spearman correlation
between gene signature and protein expression and the P value was calculated
using Partek Genomics Suite 6.6 software. Group size was determined based on the
results of preliminary experiments and no statistical method was used to pre-
determine sample size in animal studies. All histopathological results were blinded
to pathologists, and the evaluation reports, including the classiﬁcation of different
groups, are provided by pathologists. All the bioinformatics and statistical analyses
were analyzed or conﬁrmed by bioinformaticians. The genotyping of mice was
conducted by Transnetyx. All the array experiments were unbiasedly conducted
and analyzed by core facilities. All qRT-PCR experiments were performed in a
blinded manner. The rest of group design and outcome analysis were not per-
formed in a blinded manner. Statistical signiﬁcance was considered for all the
datasets when the P value was less than 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Microarray data were deposited in the Gene Expression Omnibus (GEO, accession
GSE111313, GSE111314 and GSE111335). Different detailed data are provided in
Supplementary Data 1−5. All detailed information of key reagents, including the dilution
of antibodies, was listed in Supplementary Data 5. All other data supporting the ﬁndings
of this study are available from the corresponding author upon reasonable request.
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